Late-Breaking SMA Treatment Insights You May Have Missed in February

Late-Breaking SMA Treatment Insights You May Have Missed in February

February wrapped up with a surge of data on SMA, including novel investigations into how combinatorial therapies may provide new advantages to those with the disease. More information on how nusinersen impacts patients has also become available, as have new findings...
SMA in Late February: Roche’s Sunfish Trial, Intrathecal Nusinersen Treatment & More

SMA in Late February: Roche’s Sunfish Trial, Intrathecal Nusinersen Treatment & More

Perhaps the biggest SMA news this month has been the success of Roche’s Sunfish trial, but fundamental research, such as those into the mechanisms of the disease and the implications of certain interventions, continue.  Below is a roundup of the latest news and...
SMA HCP Roundup, mid-February: X-linked infantile SMA, Risdiplam News & More

SMA HCP Roundup, mid-February: X-linked infantile SMA, Risdiplam News & More

Research on SMA continues to forge ahead in 2020, with new results in from Roche’s latest investigation into its oral SMA drug, risdiplam. New tools for screening are being revealed as legislative changes are pushing more and more toward requiring infants born in the...